Cannabidiol: An overview of some pharmacological aspects

Journal of Clinical Pharmacology

Volumn 42, Issue 11 SUPPL., 2002, Pages

  Mechoulam, Raphael ^a   Parker, Linda A ^b   Gallily, Ruth ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b WILFRID LAURIER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ANTINEOPLASTIC AGENT; APOMORPHINE; CANNABIDIOL; CANNABIDIOL DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CHLORPROMAZINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DIAZEPAM; DRONABINOL; GAMMA INTERFERON; HALOPERIDOL; HU 219; INTERLEUKIN 1; IPSAPIRONE; LITHIUM CHLORIDE; NABILONE; NICOTINE; NITRIC OXIDE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; RIMONABANT; SEROTONIN ANTAGONIST; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CATALEPSY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; HYDROLYSIS; NAUSEA; NEUROPROTECTION; NONHUMAN; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; STEREOSPECIFICITY; TRANQUILIZING ACTIVITY; VOMITING;

EID: 0036838389     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.2002.tb05998.x     Document Type: Review

References (87)

1. Mechoulam R, Hanus L: Cannabidiol: an overview of some chemical and pharmacological aspects: Part I. Chemical aspects. Chem Phys Lipids. In press.
2. Loewe S: Cannabiswirkstoffe und pharmakologie der cannabinole. Archiv Exper Pathol Pharmakol 1950;211:175-193.
3. Mechoulam R, Shani A, Edery H, Grunfeld Y: The chemical basis of hashish activity. Science 1970;169:611-612.
4. Zuardi AW, Guimaraes FS, Guimaraes VMC, Del Bel EA: Cannabidiol, in: Grotenhermen F (ed.), Cannabis und Cannabinoide. Berlin: Verlag Hans Huber, 2001;383-393.
5. Carlini EA, Leite JR, Tanhauser M, Berardi AC: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 1973;25:664-665.
6. Izquierdo I, Orsingher OA, Berardi AC: Effect of cannabidiol and other Cannabis sativa compounds on hippocampal seizures discharges. Psychopharmacol 1973;28:95-102.
7. Turkanis SA, Cely W, Olsen DM, Karler R: Anticonvulsant properties of cannabidiol. Res Communic Chem Pathol Pharmacol 1974;8:231-246.
8. Consroe P, Wolkin A: Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977;201:26-32.
9. Chesher GB, Jackson DM, Malor RM: Interaction of Delta-9-tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions. J Pharm Pharmacol 1975;27:608-609.
10. Karler R, Turkanis SA: The antiepileptic potential of the cannabinoids, in: Cohen S, Stillman RC (eds.), The Therapeutic Potential of Marihuana. New York: Plenum, 1976;383-397.
11. Tamir I, Mechoulam R, Meyer AY: Cannabidiol and phenytoin: A structural comparison. J Med Chem 1980;23:220-223.
12. Consroe P, Snider SR: Therapeutic potential of cannabinoids in neurological disorders, in: Mechoulam R (ed.), Cannabinoids as Therapeutic Agents. Boca Raton, FL: CRC Press, 1986;21-49.
13. Consroe P, Sandyk R: Potential role of cannabinoids for therapy of neurological disorders, in: Murphy L, Bartke A (eds.), Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Boca Raton, FL: CRC Press, 1992;459-524.
14. Consroe P: Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998;5:534-551.
15. Leite JR, Carlini EA, Lander N, Mechoulam R: Anti-convulsant effect of (-) and (+) isomers of CBD and their dimethyl heptyl homologs. Pharmacol 1982;124:141-146.
16. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde D, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V: Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-852.
17. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ: Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 2001;28:51-57.
18. Rosenkrantz H, Fleischman RW, Grant RJ: Toxicity of short-term administration of cannabinoids to rhesus monkeys. Toxicol Appl Pharmacol 1981;30:118-131.
19. Samara E, Bialer M, Mechoulam R: Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 1988;16:469-472.
20. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel G, Gagliardi R, Sanvito EL, Lander N, Mechoulam R: Chronic administration of CBD to healthy volunteers and epileptic patients. Pharmacologia 1980;21:175-185.
21. Pickens JT: Sedative activity of cannabis in relation to its Delta-1-trans-tetrahydrocannabinol and cannabidiol content. Br J Pharmacol 1981;72:649-656.
22. Musty R: Possible anxiolytic effects of cannabidiol, in: Agurell S, Dewey WL, Willette RE (eds.), The Cannabinoids: Chemical, Pharmacological and Therapeutic Aspects. New York: Academic Press, 1984;795-813.
23. Musty RE, Conti LH, Mechoulam R: Anxiolytic properties of cannabidiol, in: Harvey DJ (ed.), Marihuana 84: Proceedings of the Oxford Symposium on Cannabis. Oxford, UK: IRL Press, 1984;713-719.
24. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG: Action of cannabidiol on the anxiety and other effects produced by Delta-9-THC in normal subjects. Psychopharmacol 1982;76:245-250.
25. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS: Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993;7:82-88.
26. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW: Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacol 1990;100:558-559.
27. Sulcova E, Mechoulam R, Fride E: Biphasic effects of anandamide. Pharmacol Biochem Behav 1998;59:347-353.
28. Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A: Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 1994;25:161-164.
29. Onaivi ES, Green MR, Martin BR: Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exper Ther 1990;253:1002-1009.
30. Monti JM: Hypnotic like effects of cannabidiol in the rat. Psychopharmacol 1977;55:263-265.
31. Carlini EA, Cunha JM: Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21:417S-427S.
32. Zuardi AW, Rodrigues JA, Cunha JM: Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacol 1991;104:260-264.
33. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R: Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56:485-486.
34. Schneider U, Borsutzky M, Seifert J, Leweke FM, Huber TJ, Rollnik, JD, Emrich HM: Reduced binocular depth inversion in schizophrenic patients. Schizophr Res 2002;53:101-108.
35. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM: Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 2000;66:175-181.
36. Gerth CW, Schultze-Lutter F, Mauss C, Ruhrmann S, Klosterkotter J, Leweke FM: B113: The natural cannabinoid cannabidiol in the treatment of acute schizophrenia. Schizophr Res (SI Suppl) 2002;53:192.
37. Feldmann M: Development of anti-TNF therapy for rheumatoid arthritis. Nature Revs Immunol 2002;2:364-371.
38. Murray HW, Cohn ZA: Mononuclear phagocyte antimicrobial and antitumor activity: The role of oxygen intermediates. J Invest Dermatol 1980;74:285-288.
39. Moncada S, Palmer RM, Higgs EA: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-142.
40. MacMicking J, Xie QW, Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-350.
41. Klein TW, Newton C, Friedman H: Cannabinoid receptors and immunity. Immunol Today 1998;19:373-381.
42. Formukong EA, Evans AT, Evans FJ: Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 1998;12:361-371.
43. Watzl B, Scuderi P, Watson RR: Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferongamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol 1991;13:1091-1097.
44. Srivastava MD, Srivastava BI, Brouhard B: Delta-9-tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacol 1998;40:179-185.
45. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldman M: The non-psychoactive cannabisconstituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97:9561-9566.
46. Andrews PLR, Rapeport WG, Sanger GJ: Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988;9:334-341.
47. Morrow GR, Hickok JT, Rosenthal SN: Progress in reducing nausea and emesis: Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995;76:343-357.
48. Grinspoon L, Bakalar JB: Marihuana, the Forbidden Medicine. New Haven, CT: Yale University Press, 1997.
49. Doblin RE, Kleinman MA: Marijuana as antiemetic medicine: A survey of oncologists experiences and attitudes. J Clin Oncol 1991;9:1314-1319.
50. Orr LE, McKernan JF: Antiemetic effect of Delta-9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 1981;21:8-9.
51. Sallan SE, Zinberg NE, Frei E III: Antiemetic effect of Delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293:795-798.
52. Mechoulam R, Hanus L, Fride E: Towards cannabinoid drugs - Revisited. Progress in Medicinal Chemistry 1998;35:199-243.
53. Iversen LL: The Science of Marijuana. New York: Oxford University Press, 2000.
54. Darmani NA: Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav 2001;69:239-249.
55. Darmani NA: Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR-141716A. Neuropsychopharmacol 2001;24:198-203.
56. Himmi T, Dallaporta M, Perrin J, Orsini JC: Neuronal responses to Delta9-tetrahyrocannabinol in the solitary tract nucleus. Eur J Pharmacol 1996;312:273-279.
57. Spector AC, Breslin P, Grill HJ: Taste reactivity as a dependent measure in the rapid formation of conditioned taste aversion: A tool for the neural analysis of taste-visceral associations. Behav Neurosci 1998;102:942-952.
58. Eckel LA, Ossenkopp KP: Area postrema mediates the formation of rapid, conditioned palatability shifts in lithium-treated rats. Behav Neurosci 1996;110:202-212.
59. Parker LA: Rewarding drugs produce taste avoidance, but not taste aversion. Neurosci Biobehav Revs 1995;19:143-151.
60. Parker LA: Emetic drugs produce conditioned rejection reactions in the taste reactivity test. J Psychophysiol 1998;12:3-13.
61. Grill HC, Norgren R: The taste reactivity test: I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 1978;143:263-279.
62. Parker LA: Nonconsummatory and consummatory behavioral CRs elicited by lithium- and amphetamine-paired flavors. Learning Motivation 1982;13:281-303.
63. Parker LA: Behavioral conditioned responses across multiple conditioning/testing trials elicited by lithium- and amphetamine-paired flavors. Behav Neural Biology 1984;41:190-199.
64. Parker LA: Taste reactivity responses elicited by cocaine-, phencyclidine- and methamphetamine-paired sucrose solutions. Behav Neurosci 1993;107:118-129.
65. Pelchat ML, Grill HJ, Rozin P, Jacobs J: Quality of acquired responses to tastes by Rattus norvegicus depends on type of associated discomfort. J Comp Psychol 1983;97:140-153.
66. Cordick N, Parker LA, Ossenkopp KP: Rotation-induced conditioned rejection in the taste reactivity test. Neuroreport 1999;10:1557-1559.
67. Parker LA, McLeod KB: Chin rub CRs may reflect conditioned sickness elicited by a lithium-paired sucrose solution. Pharmacol Biochem Behav 1991;40:983-986.
68. Limebeer CL, Parker LA: Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned disgust reactions produced by cyclophoshamide: A rat model of nausea. Neuroreport 1999;10:3769-3772.
69. Limebeer CL, Parker LA: Ondansetron interferes with the establishment and the expression of conditioned disgust reactions: A rat model of nausea. J Exper Psychol: Anim Behav Process 2000;26:371-384.
70. Parker LA, Mechoulam R, Schlievert C: Cannabidiol, a nonpsychoactive component of cannabis, and its dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002;13:567-570.
71. Berger B, Wise CD, Stein L: Area postrema damage and bait shyness. J Comp Physiol Psychol 1973;82:475-479.
72. Bernstein IL, Chavez M, Allen D, Taylor EM: Area postrema mediation of physiological and behavioral effects of lithium chloride in the rat. Brain Res 1992;575:132-137.
73. Ritter RC, McGlone JJ, Kelley KW: Absence of lithium induced taste aversion after area postrema ablation. Brain Res 1980;201:501-506.
74. Rabin BM, Hunt WA: Effects of antiemetics on the acquisition and recall of radiation and lithium chloride induced conditioned taste aversions. Pharmacol Biochem Behav 1983;18:629-636.
75. Ossenkopp KP, Eckel LA: Toxin-induced conditioned changes in taste reactivity and the role of the chemosensitive area postrema. Neurosci Biobehav Rev 1995;19:99-108.
76. Grundy D: Visceral afferents and their modulation in animal models of nausea and vomiting. Paper presented at the International Symposium on Nausea and Vomiting: A Multidisciplinary Approach, Tutzing, Germany, June 1998.
77. Blackshaw LA, Grundy D: Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret. J Auton Nerv Syst 1993;45:41-50.
78. Blackshaw LA, Grundy D: Effects of 5-hydroxytryptamine (5-HT) on the discharge of vagal mechanoreceptors and motility in the upper gastrointestinal tract of the ferret. J Auton Nerv Syst 1993;45:51-59.
79. Hillsley K, Kirkup AJ, Grundy D: Direct and indirect actions of 5-HT on the discharge of mesenteric afferent fibres innervating the rat jejunum. J Physiol 1993;506:551-561.
80. Parker LA, Gillies T: THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav Neurosci 1995;109:71-78.
81. Breivogel CS, Griffin G, Di Marzo V, Martin BR: Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001;60:155-163.
82. Hajos N, Ledent C, Freund TF: Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001;106:1-4.
83. Monory K, Tzavara ET, Lexime J, Ledent C, Parmentier M, Borsodi A, Hanoune J: Novel, not adenylyl cyclase coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun 2002;292:231-235.
84. Ford WR, Honan SA, White R, Hiley CR: Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilator responses in rat isolated hearts. Br J Pharmacol 2002;135:1191-1198.
85. 1 receptor-deficient mice. Hypertension 2002;39:251-257.
86. 2 receptors. Proc Natl Acad Sci USA 1999;96:14136-14141.
87. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998;95:8268-8273.